Kerendia's high cost is attributed to several factors, including its novel mechanism of action, extensive research and development, and the complex manufacturing processes involved [1]. As a relatively new medication, its pricing also reflects the initial market exclusivity granted to protect the significant investment made by its developer [2].
How does Kerendia work to lower kidney damage risk?
Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist. It works by blocking the effects of excess aldosterone, a hormone that can contribute to inflammation and fibrosis in the kidneys and heart, thereby reducing the progression of chronic kidney disease (CKD) and cardiovascular complications in patients with type 2 diabetes [3][4].
When does Kerendia's patent protection end?
Patent information for Kerendia indicates that its primary patents are expected to expire in the mid-2030s, with some potentially extending into the early 2040s [5]. DrugPatentWatch.com provides detailed information on these patent expiries [5].
Are there any generic versions of Kerendia available?
Currently, there are no generic versions of Kerendia available. Generic competition typically emerges after the expiration of relevant patents and exclusivities [5].
What clinical trials support Kerendia's effectiveness?
Kerendia's efficacy has been demonstrated in several large-scale clinical trials, including the FIDELIO-DKD and FIGARO-DKD studies. These trials showed that Kerendia significantly reduced the risk of kidney disease progression and cardiovascular events in patients with CKD and type 2 diabetes compared to placebo [3][4].
What are the main side effects of Kerendia?
Common side effects reported for Kerendia include hyperkalemia (high potassium levels), hypotension (low blood pressure), and fatigue. Patients are advised to monitor their potassium levels regularly, especially when starting or adjusting the dosage of Kerendia [3][4].
How does Kerendia compare to other CKD treatments?
Unlike other CKD treatments that focus on blood pressure or glucose control, Kerendia targets the underlying inflammatory and fibrotic pathways associated with mineralocorticoid receptor overactivation. This unique mechanism offers a complementary approach to existing therapies for patients with type 2 diabetes and CKD [3][4].
Who developed and manufactures Kerendia?
Kerendia was developed and is manufactured by Bayer [1].